Your browser doesn't support javascript.
loading
A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.
Mannis, Gabriel N; Andreadis, Charalambos; Logan, Aaron C; Damon, Lloyd E; Benet, Leslie Z; Ai, Weiyun Z; Gaensler, Karin M L; Kaplan, Lawrence D; Koplowicz, Yelena B; Linker, Charles A; Olin, Rebecca L; Sayre, Peter H; Smith, Catherine C; Sudhindra, Akshay; Venstrom, Jeffrey M; Wolf, Jeffrey L; Martin, Thomas G.
Afiliación
  • Mannis GN; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA.
  • Andreadis C; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA.
  • Logan AC; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA.
  • Damon LE; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA.
  • Benet LZ; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA.
  • Ai WZ; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA.
  • Gaensler KM; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA.
  • Kaplan LD; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA.
  • Koplowicz YB; Department of Clinical Pharmacy, University of California, San Francisco, CA.
  • Linker CA; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA.
  • Olin RL; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA.
  • Sayre PH; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA.
  • Smith CC; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA.
  • Sudhindra A; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA.
  • Venstrom JM; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA.
  • Wolf JL; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA.
  • Martin TG; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA. Electronic address: tmartin@medicine.ucsf.edu.
Clin Lymphoma Myeloma Leuk ; 15(6): 377-83, 2015 Jun.
Article en En | MEDLINE | ID: mdl-25776193
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Busulfano / Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas / Acondicionamiento Pretrasplante / Agonistas Mieloablativos / Etopósido Tipo de estudio: Prognostic_studies Límite: Adult / Humans / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Busulfano / Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas / Acondicionamiento Pretrasplante / Agonistas Mieloablativos / Etopósido Tipo de estudio: Prognostic_studies Límite: Adult / Humans / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Canadá